Danvatirsen

DB14825InvestigationalGene Therapies

Danvatirsen is under investigation in clinical trial NCT03334617 (Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy.).

Mechanism: Pharmacologically active on Signal transducer and activator of transcription 3
Curator reviewed
Code names: AZD9150 · ISIS 481464

Resolves to

Compound

UNII31N550RD05CAS1402357-06-5

Targets

P40763STAT3

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

15Clinical trialsPhase, status and sponsor resolved per trial

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Danvatirsen, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account